HERTHENA-Lung01：HER3-DXd / Patritumab Deruxtecan 用于 EGFR-TKI + 铂化疗后
类型: II期临床试验 / ADC 发表日期: 2023-09-10 入库日期: 2026-05-21 来源: PubMed / Journal of Clinical Oncology 标签: EGFR L858R, HER3-DXd, Patritumab deruxtecan, ADC, 奥希替尼后, 铂化疗后
Citation
Yu HA, et al. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated Non-Small-Cell Lung Cancer After EGFR Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy. Journal of Clinical Oncology. 2023. PMID: 37689979. DOI: 10.1200/JCO.23.01476
ClinicalTrials.gov: NCT04619004
Why it matters for mom
Mom has already received osimertinib plus platinum/pemetrexed-style treatment. HER3-DXd is directly relevant as a post-EGFR-TKI, post-platinum antibody-drug conjugate strategy, though access depends on approvals/trials and toxicity tolerance.
Practical takeaways
- This is an ADC option to track for later-line EGFR-mutant NSCLC.
- It is not selected by a classic resistance mutation like MET amplification; HER3 expression is common in EGFR-mutant NSCLC.
- Key risks to discuss for deruxtecan ADCs include interstitial lung disease/pneumonitis and marrow suppression.
Questions for doctors
- Is HER3-DXd available through trial, compassionate access, or approved channels in the treating region?
- Would mom's marrow reserve and lung status make an ADC too risky?
- Are there trials that allow prior osimertinib + platinum/pemetrexed?